Cystic fibrosis breathing study pulled before it started
NCT ID NCT03655249
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study planned to test whether a specific breathing technique called autogenic drainage helps clear mucus and improve lung function in people with cystic fibrosis. The study was withdrawn before enrolling any participants, so no results are available. It would have measured changes in lung ventilation using a test called lung clearance index.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- autogenic drainage (a breathing technique)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Started
-
Aug 2018
- Expected to finish
-
Dec 2025
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
6 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Cystic fibrosis diagnosis * FEV1 \> 40% * Able to sustain 30min of chest physiotherapy Exclusion Criteria: * Presence of Burkoldheria cepacia or non tuberculous mycobacteria * Orthopedic, neuromuscular or cardiac disorder likely to impact respiratory system * Need for supplemental oxygen * Cardiac pacemaker or internal cardiac defibrillator
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cystic fibrosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cliniques universitaires Saint-Luc
Brussels, 1200, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Device-Preserved donor lungs boost transplant success?
- Can a simple questionnaire reveal why some cystic fibrosis patients skip physiotherapy?
- Cystic fibrosis diabetes: do gut hormones and genes hold the key?
- Can a special lung scan catch cystic fibrosis damage earlier than standard tests?
- Can a pill replace the liquid? testing a new form of cystic fibrosis drug
- Triple therapy under the microscope: does it transform cystic fibrosis care?